Physician profile
Robert Goodwin
NPI 1215051164
$3,089.86
in general payments reported to CMS, 2019-2025
9 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $69.19 · 2022: $266 · 2023: $761 · 2024: $1,132 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,219.20 | 2020-2025 | Caplyta |
| Abbvie INC. | $761.68 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $435.16 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $227.65 | 2019 | |
| Alkermes, INC. | $195.29 | 2023-2024 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $122.06 | 2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $94.20 | 2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $19.56 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goodwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.